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Abstract
Objectives: To establish how the terms recommended by the European Commission 
to describe side- effect risk in patient information leaflets (PILs) influences expecta-
tions of side- effects and to identify factors associated with these side- effect 
expectations.
	;vb]mĹA cross- sectional online survey was carried out by a market research company.
Setting: Data were collected in England between 18th March and 1st April 2016.
-u|b1br-m|vĹA total of 1003 adults aged between 18 and 65. Main outcome meas-
ures: Self- reported expectation that the described side- effects would affect partici-
pants if they took the medicine, measured on a likelihood scale from 1 (very unlikely) 
to 5 (very likely).
Results: Participants formed high expectations of side- effects for very common and 
common side- effects, with 51.9% and 45.0% of participants rating these as very likely or 
likely to happen to them, respectively. This fell to 8.1% for uncommon, 5.8% for rare 
and 4.1% for very rare. For each descriptor, higher expectations of side- effects were more 
associated with women or being from an ethnic minority, or having less education, a house-
hold illness, high perceived sensitivity to medicines or negative beliefs about medicines.
	bv1vvbomĹThe current use of verbal descriptors to communicate side- effect risk in 
PILs leads to high side- effect expectations. These expectations could contribute to 
nocebo- induced medication side- effects experienced by patients. Additional work is 
required to identify ways to improve the way risk information is conveyed in PILs.
  + )  ! 	 "
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Medications may generate adverse reactions, with studies show-
ing that around 6.5% of patient admissions to hospitals are related 
to an adverse drug reaction (ADR).1 ADRs are noxious, unintended 
responses to medication which occur at normal doses.2 Medication 
side- effects such as these can significantly reduce patient adherence3 
often leading to reduced therapeutic benefit for the patient. They also 
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mean financial costs for health services as they are a major cause of 
hospital admissions, and emergency department and outpatient care 
visits.4
Not all side- effects are related to the physiological action of 
the medication, however.5 For example, it has been noted that only 
10.9% of adverse reactions reported to common prescription drugs 
are clearly attributable to the medication.6 Many other, non- specific, 
side- effects may occur due to a nocebo effect.7 Nocebo effects have 
been described as the flip side to the placebo effect, whereby an ad-
verse reaction is experienced by someone who receives an inert ex-
posure.8 From a recent systematic review, we know that expectations 
such as those generated from verbal suggestions of what symptoms to 
expect are one of the strongest factors affecting the development of 
nocebo effects.9 Expectations have also been found to contribute to 
the side- effects that patients experience from their medications.10,11 
This is a problem as side- effects are an important cause of patient 
non- adherence.3,12
One of the main ways that patients can generate these negative 
expectations of their medication is by reading the accompanying 
patient information leaflet (PIL). Over 70% of patients will read the 
accompanying PIL for a newly prescribed medication.13 In Europe, 
all medicines prescribed or sold over the counter must be distrib-
uted with a comprehensive PIL.14 In 1998, European Commission 
(EC) guidelines advised PILs should group side- effects according to 
five frequency bands, using a different verbal label for each one.15 
As such, side- effects could be grouped into very common (affect 
more than 1 in 10 patients), common (up to 1 in 10), uncommon 
(up to 1 in 100), rare (up to 1 in 1000) or very rare (up to 1 in 
10 000).
However, as the guidelines were published, several studies have 
shown that these verbal labels are problematic, leading to overesti-
mations by samples of students, patients and health- care profession-
als.1623 As such, current guidelines suggest combining verbal and 
frequency expressions (eg, very common, more than 1 in 10 peo-
ple).24 Although it has been shown that this may not lead to more 
accurate side- effect risk estimates than the verbal format25 and still 
leads to significant risk overestimations when compared to numerical 
frequency bands alone.26 In part, patient estimations seem to depend 
on the type of side- effect with mild side- effects generally resulting 
in higher estimations than severe side- effects.19
Although previous studies have looked at how these verbal de-
scriptors affect peoples numerical estimation of side- effects, they 
have not looked at how they affect peoples subsequent expectations 
of side- effects. The two issues are linked, but not identical. It is possi-
ble for an optimistic patient to believe that symptoms are common but 
unlikely to affect them personally, and vice versa. This is important as 
it is these expectations that may trigger a nocebo response. This study 
investigated peoples expectations of side- effects when described 
using EC recommended descriptors. We also tested whether these 
expectations are associated with demographic and psychological 
characteristics such as beliefs about medicines, optimism or perceived 
sensitivity to medicines which have previously been implicated in the 
nocebo literature.5,27
Our specific aims were to
1. Assess peoples expectations of side-effects from the EC rec-
ommended risk descriptors
2. Investigate if these expectations differ depending on whether they 
relate to mild or severe side-effects.
3. Determine whether demographic factors (age, gender, ethnicity, 
employment status, level of education or presence of a household 
illness) are associated with the expectation of experiencing a side-
effect after taking a medicine labelled with one of the EC recom-
mended risk descriptors.
4. Determine whether psychological factors (optimism, perceived 
sensitivity to medicines, belief about medicines, health anxiety, 
health literacy or PIL reading behaviour) are associated with the 
expectation of experiencing a side-effect after taking a medicine 
labelled with one of the EC recommended risk descriptors.
5. Determine if participants understanding of what the verbal de-
scriptors mean is associated with their subsequent expectations of 
side-effects.
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The market research company Ipsos MORI conducted an online sur-
vey of adults aged between 18 and 65 living in England on our behalf, 
between 18th March and 1st April 2016. This study was approved by 
the Psychiatry, Nursing and Midwifery Research Ethics Committee at 
Kings College London (ref: HR- 15/16- 2104).
The same study was used to assess in detail factors associated 
with how patients understand the numerical risk information con-
veyed by verbal labels of risk, the results of which have been submit-
ted elsewhere.
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Participants were recruited by Ipsos MORI using their existing da-
tabase of people living in England and interested in taking part in 
Internet surveys (approximate n=160 000). We excluded over 65s 
because of concerns about the representativeness of this group in 
Internet surveys.28,29 Potential participants were emailed a link to 
the survey. After providing informed consent, participants were al-
located by the survey software to receive questions about either mild 
or severe side- effects. The allocation was based on which condition 
had the lowest number of completed responses at that time. Panel 
participants received points for completing the survey equivalent to 
75 pence.
ƑĺƒՊ|Պ"-lrѴ;vb;
We used quotas based on the National Readership Survey30 to ensure 
that the sample reflected the demographic profile of 18- to 65- year- olds 
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in England. This is standard method for this form of research to ensure 
samples are representative of the adult English population. These quo-
tas were based on participant age and gender (interlocked), location 
and working status. A priori we intended to recruit 1000 participants to 
provide us with a sample error of about plus or minus 3%.
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Where possible, we included or adapted items that had been previously 
developed and tested for their reliability and validity and that have been 
widely used in the literature. Using opportunity sampling, we piloted all 
items with five members of the general public who read through the 
questionnaire with the researcher and identified anything that was not 
clear. We rephrased items where necessary to improve clarity. See sup-
porting information for full copy of the questionnaire with top line results.
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Five items were used to assess participant expectations of side- effects. 
Depending on which condition they had been assigned to, participants 
were told that a new drug had been developed with either dizziness 
or kidney failure as one of its side- effects. The side- effect was de-
scribed using each of the five EC recommended combined verbal and 
frequency expressions (eg, very common, may affect more than 1 in 
10 people) which were presented in a random order. Participants were 
asked to rate how likely they were to experience dizziness or kidney 
failure if they took the drug on a five point scale ranging from very 
unlikely to very likely.
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Participants were asked about their age, gender, ethnicity, highest 
level of education, employment status and whether they or anyone 
in their household had a long- standing illness, disability or infirmity.
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A single item to assess health literacy was adapted from elsewhere31 
and asked participants to state how often they needed help reading 
PILs. We also included one question which asked how often partici-
pants read PILs when taking a new medication. Response options 
for both ranged from 1 (never) to 5 (always). We assessed health 
anxiety using one question from the health anxiety inventory.32 This 
asked participants to rate themselves from 1 I do not worry about 
my health to 4 I spend most of my time worrying about my health.
The Revised Life Orientation Test33 was used to rate participant 
optimism. This has six questions and provides a score from 6 (least op-
timism) to 30 (most optimism). We used the overuse and harm general 
subscales from the Beliefs about Medicines Questionnaire (BMQ)34 
to measure attitudes towards medicines in general. These subscales 
give scores from 4 to 20, with higher scores indicating higher per-
ceived overuse or harm. The Perceived Sensitivity to Medicines scale35 
was used to assess how sensitive participants thought they were to 
medicines. This provides a score from 5 to 25 with higher scores indi-
cating higher sensitivity.
ƑĺѶՊ|Պ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descriptors
We included five items (presented in a random order) to assess partici-
pant understanding of the side- effect risk descriptors (very common, 
common, uncommon, rare and very rare). These asked people 
to consider a PIL for an imaginary drug which stated, for example, 
that nausea is common. Participants were asked to estimate how 
many out of 10 000 people who take the drug would develop that 
side- effect. Participants were asked about either mild side- effects 
(headache or nausea) or severe side- effects (seizure or difficulty 
breathing) depending on which condition they had been assigned to.
ƑĺƖՊ|Պm-Ѵvbv
Participants expectations were grouped by likelihood to see the fre-
quency that each likelihood statement was selected for the different 
risk descriptors. We carried out a series of chi- squared tests to see 
whether participant expectations differed between mild and severe 
side- effects. For occurrences where the expected cell count was 
below 5, Fishers exact test was used instead.
Ordinal regressions were carried out to identify if any demographic 
or psychological characteristics, or how well participants estimated 
the EC recommended descriptors, were associated with expectations 
of personally experiencing side- effects. The dependent variable for 
each regression was participants scores on the likelihood scale for 
each verbal descriptor. For each regression, all demographic variables 
and side- effect type (mild or severe) were added in one block, and 
each psychological variable was added on its own, controlling for the 
previously entered variables.
For all analyses, answers of dont know or prefer not to say were 
excluded. Only 3% of participants answered dont know, and 1% an-
swered prefer not to say for any question where this was an option. 
Analyses were carried out using SPSS 22. As participant expectations 
did not change by more than 0.2% when using data weighted by age, 
gender, region and working status, our analyses used unweighted data.
ƒՊ |Պ!"&$"
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A total of 1003 participants completed the survey and were included 
in the final sample (see Figure 1 for response rates). Demographic in-
formation for the participants is given in Table 2.
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Table 1 shows participant expectations of side- effects for each of 
the descriptors. Expectations of side- effects varied widely for each 
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descriptor; however, the majority of participants thought that very 
common and common side- effects were very likely or likely to hap-
pen to them (51.9% and 45%, respectively) despite these terms only 
being intended to represent a risk of around 1 in 10 patients being 
affected. Expectations of side- effects dropped substantially for un-
common, rare and very rare with 8.1%, 5.8% and 4.1% of par-
ticipants thinking there were very likely or likely to experience the 
side- effects, respectively.
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participant expectations?
The difference in expectations between mild and severe side- effects 
is shown in Table 1. There was no difference in expected likelihood 
between mild and severe side- effects except for side- effects de-
scribed as rare in which expectations were lower for mild vs severe 
side- effects, P=.003.
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expectations?
Table 2 shows the association between demographic variables 
and perceived likelihood of experiencing side- effects, with all 
demographic variables controlled for each other. Men were 31% 
less likely than women to have higher expectations of side- effects 
described as being very common or common. Participants from 
ethnic minorities were more likely to have higher expectation of 
side- effects being as common, uncommon, rare and very rare. 
Compared to those with a university degree, participants with no 
academic qualifications were more likely to have a higher expecta-
tion of side- effects described as uncommon, rare and very rare. 
Similarly compared to having a university degree, participants with 
school qualifications were more likely to have a higher expectation of 
side- effects described as uncommon, rare and very rare. Having an 
illness or an illness in the household increased expectations of side- 
effects compared to having no household illness but this was only 
significant for some of the descriptors (very common, common 
and uncommon).
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expectations?
Table 2 shows the association between psychological variables and 
perceived likelihood of experiencing side- effects, controlling for de-
mographic characteristics. People with a higher perceived sensitivity 
to medicines were 5%- 10% more likely to have higher expectations 
of side- effects described using each of the descriptors compared to 
those with a lower perceived sensitivity to medicines. Participants 
who thought medicines were overused or caused harm were 5%- 
10%, and 7%- 20%, respectively, more likely to have higher expecta-
tions of side- effects described as common, uncommon, rare or 
very rare. Participants scoring higher on health anxiety were 25% 
more likely to have higher expectations of side- effects described 
as very common compared to those with lower health anxiety. 
Participants who needed help reading PILs were 14%- 49% more 
likely to have higher expectations of side- effects described as com-
mon, uncommon, rare and very rare. Participants who read PILs 
more often were 12% less likely to have higher expectations of side- 
effects described as very rare compared to those who read PILs less 
often. There was no effect of optimism on participants side- effect 
expectations.
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descriptors associated with their subsequent side- 
effect expectations?
Whether participants estimated each of the EC recommended de-
scriptors in accordance with the corresponding EC frequency band 
had little effect on their side- effect expectations, apart from the de-
scriptor very rare and uncommon. Participants who overestimated 
the number of patients likely to experience a very rare side- effect 
were 45% less likely to have higher expectations of very rare side- 
effects, and participants who underestimated the intended meaning 
of uncommon were 54% more likely to have higher expectations of 
uncommon side- effects. Full results of participants estimations have 
been submitted elsewhere.
 &! ƐՊParticipant flow through the survey.  
Eligibility check was used to confirm participants age in case this had 
changed since they were emailed the link.  
* Completing the survey too quickly to have given genuine, 
considered answers, or providing identical answers to five or more 
consecutive questions where this was possible.
11 657 people listed as age 
18-65 were emailed the 
study link
1155 clicked on study link
9 dropped out upon reading 
the information sheet
1146 gave consent and 
examined for eligibility
37 were excluded due to 
being identified as 
“speeding or 
straightlining”*
10 502 did not respond
1144 confirmed eligible 
and started survey
1040 completed the survey
2 dropped out during 
eligibility check
1003 included in the final 
sample
104 dropped out during 
survey
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There are several key findings from our work. First, when pre-
sented with the standard format of side- effect risk information 
that is currently used in PILs, people form high expectations 
about their personal likelihood of experiencing symptoms, with 
the majority of people thinking very common or common side- 
effects are likely to happen to them, despite those descriptors 
only representing a risk of around 1 in 10 people being affected. 
However, these expectations are formed independently from 
probability estimates. Under, over or correctly estimating the nu-
merical meaning of a side- effect risk descriptor had little bearing 
on whether a patient felt that they, personally, would experience 
it. These high side- effect expectations are problematic, as they 
$ ƐՊExpected likelihood of minor (dizziness) and severe (kidney failure) side- effects from an imagined new drug using the EC 
recommended combined descriptors
Current guidelines Expectancy Mild, n (%) Severe, n (%) $o|-ѴķmŐѷő
Very common (more than 1 
in 10)
Very likely 115 (22.7) 106 (21.3) 221 (22.0)
Likely 152 (30.0) 148 (29.8) 300 (29.9)
About as likely as not 118 (23.3) 128 (25.8) 246 (24.6)
Unlikely 91 (18.0) 79 (15.9) 170 (16.9)
Very unlikely 20 (4.0) 20 (4.0) 40 (4.0)
Dont know 10 (2.0) 16 (3.2) 26 (2.6)
Chi- square test χ2=1.443, P=.837
Common (up to 1 in 10) Very likely 58 (11.5) 63 (12.7) 121 (12.1)
Likely 175 (34.6) 155 (31.2) 330 (32.9)
About as likely as not 122 (24.1) 132 (26.6) 254 (25.3)
Unlikely 121 (23.9) 114 (22.9) 235 (23.4)
Very unlikely 20 (4.0) 19 (3.8) 39 (3.9)
Dont know 10 (2.0) 14 (2.8) 24 (2.4)
Chi- square test χ2=1.874, P=.759
Uncommon (up to 1 in 100) Very likely 7 (1.4) 10 (2.0) 17 (1.7)
Likely 32 (6.3) 32 (6.4) 64 (6.4)
About as likely as not 92 (18.2) 103 (20.7) 195 (19.4)
Unlikely 215 (42.5) 217 (43.7) 432 (43.1)
Very unlikely 154 (30.4) 121 (24.3) 275 (27.4)
Dont know 6 (1.2) 14 (2.8) 20 (2.0)
Chi- square test χ2=4.827, P=.306
Rare (up to 1 in 1000) Very likely 3 (0.6) 7 (1.4) 10 (1.0)
Likely 28 (5.5) 20 (4.0) 48 (4.8)
About as likely as not 56 (11.1) 72 (14.5) 128 (12.8)
Unlikely 136 (26.9) 169 (34.0) 305 (30.4)
Very unlikely 278 (54.9) 218 (43.9) 496 (49.5)
Dont know 5 (1.0) 11 (2.2) 16 (1.6)
Chi- square test *=15.452, P=.003
Very Rare (up to 1 in 10 000) Very likely 5 (1.0) 6 (1.2) 11 (1.1)
Likely 15 (3.0) 15 (3.0) 30 (3.0)
About as likely as not 38 (7.5) 51 (10.3) 89 (8.9)
Unlikely 65 (12.8) 70 (14.1) 135 (13.5)
Very unlikely 375 (74.1) 342 (68.8) 717 (71.5)
Dont know 8 (1.6) 13 (2.6) 21 (2.1)
Chi- square test χ2=3.495, P=.481
Chi- square analyses did not include participants who answered Dont know.
*One cell had an expected cell count of less than 5 so Fishers exact was used instead.
ƐƓƐѵՊ| ՊՊՍ
W
E
B
S
T
E
R
 
E
T
 A
L.
$ ƑՊDemographic and psychological factors associated with participant expectations that very common, common, uncommon, rare and very rare side- effects would personally affect them
Variable
oŐѷőoul;7b-m
Ő !ő
Very common Adjusted odd 
u-|bovŐƖƔѷőmƷƖƕƕ
Common Adjusted odd 
u-|bovŐƖƔѷőmƷƖƕƖ
&m1ollom7fv|;7o77
u-|bovŐƖƔѷőmƷƖѶƒ
Rare Adjusted odd ratios 
ŐƖƔѷőmƷƖѶƕ
Very rare Adjusted odd 
u-|bovŐƖƔѷőmƷƖѶƑ
Gendera
Male 492 (49.1%) 0.69 (0.46-0.92) 0.69 (0.55-0.87) 1.05 (0.83- 1.33) 0.88 (0.69- 1.12) 0.94 (0.70- 1.25)
Female 511 (50.9%) Reference Reference Reference Reference Reference
Agea 41.0 (22.0) 0.99 (0.98- 1.00) 1.00 (0.99- 1.01) 0.99 (0.98- 1.002) 1.00 (0.99- 1.01) 1.00 (0.99- 1.01)
Ethnicitya
Ethnic minorities 107 (10.7%) 1.25 (0.86- 1.83) 1.49 (1.02-2.18) 2.09 (1.42-3.07) 2.06 (1.41-3.03) 2.33 (1.53-3.56)
White 886 (88.3%) Reference Reference Reference Reference Reference
Employmenta
Not working 280 (27.9%) 1.07 (0.81- 1.39) 1.01 (0.78- 1.32) 1.02 (0.78- 1.33) 0.90 (0.68- 1.19) 0.79 (0.56- 1.10)
Working 723 (72.1%) Reference Reference Reference Reference Reference
Educationa
No academic 
qualifications
44 (4.4%) 0.82 (0.47- 1.46) 1.23 (0.69- 2.20) 3.06 (1.70-5.51) 2.73 (1.52-4.92) 4.88 (2.62-9.06)
School qualifications 387 (38.6%) 0.94 (0.74- 1.19) 0.99 (0.77- 1.25) 1.42 (1.11-1.81) 1.52 (1.18-1.96) 1.55 (1.14-2.10)
University degree 565 (56.3%) Reference Reference Reference Reference Reference
Household illnessa
Yesme 290 (28.9%) 1.27 (0.97- 1.66) 1.40 (1.07-1.83) 1.42 (1.07-1.87) 1.13 (0.85- 1.50) 1.23 (0.88- 1.71)
Yessomeone else 128 (12.9%) 1.47 (1.04-2.10) 1.78 (1.25-2.54) 1.85 (1.29-2.65) 1.17 (0.81- 1.70) 1.06 (0.68- 1.65)
No 571 (56.9%) Reference Reference Reference Reference Reference
Side- effect typea
Mild 506 (50.4%) 1.03 (0.82- 1.29) 1.00 (0.80- 1.26) 0.80 (0.63- 1.12) 0.70 (0.55-0.89) 0.77 (0.58- 1.03)
Severe 497 (49.6%) Reference Reference Reference Reference Reference
Estimates 1b
Incorrect (under for Very 
common, over for Very 
rare)
- 0.83 (0.63- 1.10) - - - 0.55 (0.37-0.83)
Correct - Reference - - - Reference
Estimates 2b
Under - - 0.94 (0.60- 1.48) 1.54 (1.10-2.16) 1.29 (0.79- 2.09) - 
Over - - 0.96 (0.70- 1.33) 1.25 (0.95- 1.64) 1.08 (0.80- 1.46) - 
Correct - - Reference Reference Reference - 
Optimismb 19.0 (6.0) 0.98 (0.95- 1.00) 0.98 (0.96- 1.01) 0.97 (0.95- 1.001) 0.98 (0.95- 1.00) 0.98 (0.95- 1.02)
(Continues)
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can be an important precursor to the development of actual side- 
effects, as a result of a nocebo effect.9 Although reading about 
side- effects does not always cause someone to experience a side- 
effect,36,37 in some situations it can.10,11 Therefore, it is important 
to reduce any unrealistically high side- effect expectations that 
PILs produce.
Second, similar to the nocebo literature,9 participants expec-
tation of side- effects described using the current guidelines does 
show associations with demographic and psychological factors. 
This will allow clinicians to be aware of those patients more at risk 
of developing nocebo- induced side- effects to their medications as 
a result of high side- effect expectations. Women are more likely 
to expect higher risk side- effects compared to Men, and people 
from ethnic minorities are more likely to expect side- effects than 
people who are White. This supports previous research that has 
shown women and people from ethnic minorities have more dread 
of potential risks/hazards in general.38 Participants with no aca-
demic qualifications and those with school qualifications are more 
likely to expect lower risk side- effects than those with university 
degrees. This may be because these participants are less familiar 
with and have difficulty interpreting the terms 1 in 1000 and 1 in 
10 000 that accompanied the verbal descriptors in these questions 
and therefore misinterpret what it means in terms of their personal 
side- effect expectations. Similarly higher health illiteracy was asso-
ciated with higher expectations of side- effects. Having a household 
illness increased expectations of side- effects compared to not hav-
ing a household illness, possibly due to an availability heuristic39 
as symptoms are more likely to be present if there is a household 
illness. Interestingly, despite being implicated in the literature on 
peoples numerical estimates of the descriptors,19 we found side- 
effect type had little effect on participants expectations. Similarly 
whether participants provided correct or incorrect risk estimates 
for the descriptors had little effect on expectations. There are two 
possible explanations for this. First, the verbal risk descriptors do 
not influence expectations. Or second, the inclusion of the numer-
ical expression draws peoples attention away from the verbal risk 
descriptor. Either way the verbal risk descriptors are ineffective at 
influencing peoples expectations. These support the view that par-
ticipants form independent expectations of side- effects from any 
generalized, numerical risk estimates.
In terms of the psychological factors, perceived sensitivity to 
medicines showed the strongest association with expectation; par-
ticipants with a higher perceived sensitivity were more likely to ex-
pect side- effects than those with a lower perceived sensitivity. In 
addition, a stronger belief that medicines are overused and cause 
harm increased the expected likelihood of side- effects. This supports 
previous research showing negative views about medicines translate 
into negative expectations.5 Perceived sensitivity to medicines and 
negative belief about medicines have also been found to determine 
side- effect reporting to vaccinations and new medication.40,41 It is 
likely that the relationship between these factors and symptom re-
porting is mediated by negative expectations. It may be important 
to combat these negative medication beliefs in the first instance to 
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reduce patients experiencing nocebo- induced side- effects as a result 
of negative expectations.
ƓĺƑՊ|ՊlrѴb1-|bomv=ouvb7;Ŋ;==;1|u;rou|bm]
guidelines and clinical practice
Verbal descriptors have long been favoured for the presentation of 
side- effect risk information.42 However, previous research including 
our own large- scale survey (submitted elsewhere) has shown that 
verbal descriptors mislead rather than inform, leading readers to 
greatly overestimate the risk of side- effects. Given that our analyses 
in this study suggest that participant estimations of the currently 
used descriptors also have little if any impact on patient expecta-
tions of their own likelihood of experiencing side- effects, the ration-
ale for using them appears to be weak. As well as having implications 
for PILs, our results also highlight the need for clinicians to assess 
patients understanding of the side- effect information and the risk 
of side- effects occurring, before explaining the likelihood of side- 
effects based on information in PILs and providing reassurance to 
patients if necessary. This is particularly important for patients with 
risk factors for overestimating their likelihood of developing side- 
effects, namely women, those with lower educational attainment, 
those with a household illness, those who seem to have difficulty 
reading health- related literature, those with a perceived sensitiv-
ity to medicine and negative beliefs about the overuse and harm of 
medicine.
ƓĺƒՊ|Պ"|u;m]|_-m7;-hm;vv;vķ-m7=|u;u;v;-u1_
This study included a large sample size of 18- to 65- year- olds in the 
English population, specifically recruited to demographically reflect 
the composition of the English population on multiple key variables 
(age, gender, location and working status). Whether members of mar-
ket research panels are psychologically representative of the general 
population in terms of attitudes to medicines and their expectations of 
side- effects are unknown, however. In addition, because we were in-
terested in participants perceptions of verbal descriptors rather than 
side- effects and also to avoid confusing participants when they came 
to answer our primary outcome questions we chose to use different 
side- effects to assess participants understanding of the descriptors 
than those used in the primary side- effect expectations outcome. It is 
plausible that had we used the same symptom in the estimation meas-
ure we would have identified stronger associations with our primary 
outcome.
Many questions used in the survey were hypothetical, asking 
participants to state their expectations of side- effects for an imag-
inary drug, for example. Future research could usefully build on this 
study by testing whether the findings hold true for patients given 
a newly prescribed medication. Due to the hypothetical nature, de-
spite research showing there is some evidence that previous expe-
rience influences nocebo effects,9 we could not assess participants 
previous experience with this imaginary drug. We did, however, in-
clude the perceived sensitivity to medicines measure which assessed 
participants past reactions to medicines in general and therefore 
acted as a proxy measure of participants experience of side- effects 
in the past. We excluded over 65s due to issues of how represen-
tative they are in online surveys. However, over 65s are the heavi-
est medication consumers,43 therefore replicating this work within 
that population would be of use. It may also be useful for future re-
search to break down ethnicity into more than two categories, to 
see whether any further differences lie within the ethnic minority 
category. Not only this there is a possibility that risk information also 
affects the perceived benefits, as well as side- effects of a medica-
tion, as such future work in these field should consider both forms 
of outcome.
Finally, we suggest that future research should explore ways 
of reducing participant expectations of side- effects. Previous 
research has shown that presenting side- effect risk with numer-
ical expressions vs verbal labels (eg, 1 in 10 vs common) results 
in lower expectations.16 Another method may be to reframe the 
numerical risk of side- effects in terms of the number/proportion 
of people who remain side- effect free (eg, 9 in 10 people will not 
experience).44 Alternatively, it may be better to use figurative risk 
representations that visually display the risk of side- effects. This 
has been shown to improve comprehension and accuracy of side- 
effect risk interpretation when displayed alongside numerical risk 
formats.17
ƔՊ |Պ&"
Members of the public commonly overestimate their own personal 
likelihood of developing the side- effects referred to in PILs using the 
current risk descriptors. This is especially true for women, ethnic mi-
norities, those less educated, those with a household illness and those 
who have a higher perceived sensitivity to medicines, and negative be-
liefs about medicines. Interestingly, however, how someone interprets 
a risk descriptor has little bearing on whether they expect to develop 
side- effects themselves. Further research is necessary in order to 
provide sufficient evidence to reach a conclusion about what should 
be done regarding verbal descriptors. In the meantime, health- care 
professionals should take care to correct any unrealistic expectations 
patients may have about medication side- effects to allow patients to 
make properly informed decisions about medication and to reduce the 
likelihood of nocebo effects.
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